tabalumab
Lilly abandons RA drug
February 8, 2013Research and Development, Sales and Marketing RA, lilly, tabalumab
Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
